A Phase 1/2 Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction of Oral Mucositis in Subjects with Locally Advanced Head and Neck Cancer (HNC) Receiving Postoperative Radiotherapy with Concurrent Chemotherapy

Trial Profile

A Phase 1/2 Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduction of Oral Mucositis in Subjects with Locally Advanced Head and Neck Cancer (HNC) Receiving Postoperative Radiotherapy with Concurrent Chemotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Sep 2015

At a glance

  • Drugs Palifermin (Primary)
  • Indications Mucositis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors Swedish Orphan Biovitrum
  • Most Recent Events

    • 15 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top